BOD Australia Ltd - Bod and Health & Happiness Group launch first CBD products in the UK
BOD Australia Ltd (ASX:BDA)

Bod and Health & Happiness Group launch first CBD products in the UK

Highlights

What's Happened

Bod Australia Limited ("Bod", ASX: BDA) has successfully launched its first CBD products to market in the UK. Products are now live in the United Kingdom under new premium brand CBII (www.cbii-cbd.com). This is part of the Company’s collaboration and exclusive licencing agreement with Health & Happiness Group Ltd.

What is CBII?

CBII has been established as a new H&H Group brand to distribute, market and sell premium CBD and hemp products to consumers. The CBII product suite includes a range of full spectrum CBD oil products derived from European Good Manufacturing Practice (GMP) hemp extracts in varying strengths (100mg, 200mg and 500mg).

file

How will sales be generated?

The products are currently available to consumers in the United Kingdom through E-commerce channels. Bod and H&H Group will expand into traditional retail within the country in the coming months. As part of the binding licencing agreement between the two parties, H&H Group will initiate marketing and brand campaigns to drive product uptake and awareness in the UK.

What does this announcement mean?

Erik Bergseng CFA® from Mawson Graham provides perspective on this recent announcement.
Erik Bergseng CFA®
Written by Erik Bergseng CFA®
Published Dec 16, 2019

This announcement is significant for BOD because it demonstrates that they have begun leveraging their strategic relationship with major shareholder H&H Group which was announced mid-2019. This development will likely lead to an additional revenue stream for BOD that is light on working capital. The U.K. is only one of the target markets that BOD wanted to focus on with its H&H partnership, with other countries of interest in the near term being the USA, France, Italy and the Netherlands. Furthermore this expansion into the U.K. also comes following BOD's announcement to expand its MediCabilis™ sales into the U.K. through a medicinal cannabis distribution agreement with PCCA Ltd.

The information within this section has been provided by Mawson Graham Pty Ltd and is for general information purposes only and is not intended to reflect any recommendations or financial advice. The information in this section has been prepared without taking into account your objectives, financial situation or needs. For this reason, you should consider the appropriateness of the advice or recommendation in light of your own personal circumstances, relevant risk factors, the nature and extent of your risk of loss, as well as the legal and accounting consequences before acting making an investment or trading decision regarding any Financial Product mentioned herein. While it is believed that all information sourced and contained within this section to be accurate at the time of publication, liability for any errors, omissions, accuracy or completeness of the information (except any statutory liability which cannot be excluded) is specifically excluded by Mawson Graham Pty Ltd, its associates, officers, directors, employees and agents. Past performance is not a reliable indicator of future performance. Important Disclosure: Mawson Graham Pty Ltd, its directors, associates and employees advise that they may hold securities, may have an interest in and/or earn brokerage, investor relations fees, corporate fees, and other benefits or advantages, either directly or indirectly from client transactions arising from any information mentioned within this section and in documents published within this section.
Mawson Graham
Mawson Graham

CEO's Summary

Jo Patterson

“This is an exciting development and a major milestone for Bod as it marks the commercialisation of our CBD consumer products and unlocks the benefits associated with the Company’s agreement with H&H Group. Having our products launched through a consumer focused, premium brand leaves Bod well positioned to capitalise on a rapidly growing market segment. We are confident that product uptake will be strong and this will underpin revenue growth for Bod. Product development initiatives remain ongoing and we are excited to have the opportunity to introduce additional lines through the CBII brand and others in the coming months. These new products will help grow market share and provide additional revenue streams for the Company.”

Jo Patterson
CEO, BOD Australia Ltd

Download Announcement

View this announcement as well as our full profile on the company.

How do I invest?

Considering investing in BOD Australia Ltd?
Here's how to get started.
Low Cost Brokerage ASX Cheapest ASX Trading Platform
  1. 1

    Create account

    Open an account with an online broker of your choice. If you do not have an existing broker, consider Mawson Graham's A$9.50 flat fee platform.

    Sign up now »
  2. 2

    Search for ASX:BDA

    On your online investment platform search for the stock ticker code ASX:BDA to bring up the company's shares.

  3. 3

    Buy shares

    Place your order however you wish. If you need advice on buying or selling, you should seek the assistance of a full service financial adviser experienced in small cap equities.

Up